m6A-centered Crosstalk Information
Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
| Crosstalk ID |
M6ACROT05023
|
[1] | |||
Non-coding RNA
ZEB1-AS1
ELAVL1
lncRNA miRNA circRNA
Direct
Enhancement
m6A modification
ZEB1
ZEB1
ELAVL1
 : m6A sites
|
|||||
| m6A Modification: | |||||
|---|---|---|---|---|---|
| m6A Regulator | ELAV-like protein 1 (ELAVL1) | READER | |||
| m6A Target | Zinc finger E-box-binding homeobox 1 (ZEB1) | ||||
| Epigenetic Regulation that have Cross-talk with This m6A Modification: | |||||
| Epigenetic Regulation Type | Non-coding RNA (ncRNA) | ||||
| Epigenetic Regulator | ZEB1 antisense RNA 1 (ZEB1-AS1) | LncRNA | View Details | ||
| Regulated Target | ELAV-like protein 1 (HuR/ELAVL1) | View Details | |||
| Crosstalk Relationship | ncRNA → m6A | Enhancement | |||
| Crosstalk Mechanism | ncRNAs directly impacts m6A modification through recruiting m6A regulator | ||||
| Crosstalk Summary | Zinc finger E-box-binding homeobox 1 (ZEB1) induced-upregulation of ZEB1-AS1 maintained the stability of ZEB1 mRNA by binding with ELAVL1, which formed a feedback loop to facilitate TNBC progression. These findings might provide a new target for TNBC treatment. | ||||
| Responsed Disease | Triple-negative breast cancer | ICD-11: 2C6Z | |||
In-vitro Model |
MDA-MB-436 | Invasive breast carcinoma of no special type | Homo sapiens | CVCL_0623 | |
| MDA-MB-453 | Breast adenocarcinoma | Homo sapiens | CVCL_0418 | ||
| MCF-7 | Invasive breast carcinoma | Homo sapiens | CVCL_0031 | ||
| MDA-MB-231 | Breast adenocarcinoma | Homo sapiens | CVCL_0062 | ||
| In-vivo Model | As previously described, Xenograft in vivo mice assay was performed.13 Transfected MDA-MB-436 or MDA-MB-453 cells with sh-ZEB1-AS1#1 or NC (sh-NC) were subcutaneously injected into mice. Every 3 days, tumor growth was monitored. | ||||